{
    "Title": "Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)",
    "URL": "https://doi.org/10.1371/journal.pntd.0008912",
    "Published": "January 7, 2021",
    "Subject_Areas": [
        "Serology",
        "Chagas disease",
        "Enzyme-linked immunoassays",
        "Drug therapy",
        "Trypanosoma cruzi",
        "Tea",
        "Parasitic diseases",
        "Polymerase chain reaction"
    ],
    "Authors": {
        "Jaime Altcheh": [
            "Hospital de Niños Ricardo Gutiérrez and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP), CONICET-GCBA, Buenos Aires, Argentina"
        ],
        "Luis Castro": [
            "Centro de Atencion e Investigacion Medica S.A. (CAIMED–Yopal), Yopal, Colombia"
        ],
        "Juan C. Dib": [
            "Universidad del Norte, Barranquilla, Colombia"
        ],
        "Ulrike Grossmann": [
            "Bayer AG, Research and Development Pharmaceuticals, Berlin, Germany"
        ],
        "Erya Huang": [
            "Bayer US LLC, Whippany, New Jersey, United States of America"
        ],
        "Guillermo Moscatelli": [
            "Hospital de Niños Ricardo Gutiérrez and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP), CONICET-GCBA, Buenos Aires, Argentina"
        ],
        "Jimy José Pinto Rocha": [
            "Fundación CEADES–Plataforma de Atención Integral a los Pacientes con Enfermedades de Chagas, Cochabamba, Bolivia"
        ],
        "Teresa Estela Ramírez": [
            "Centro de Enfermedad de Chagas y Patologias Regionales, Santiago del Estero, Argentina"
        ],
        "on behalf of the CHICO Study Group": []
    }
}